 The recently presented FOLFIRINOX regimen shows enhanced activity in metastatic pancreatic cancer patients. This regimen is, however, limited to patients with good performance status ECOG 0-1, no major comorbidity, age 75 years, and bilirubin 1.5 ULN Conroy 2011 6. The majority of pancreatic cancer patients will therefore not be treated with this regimen. 